Angewandte Chemie Paper Demonstrates PCC Ability to Enter Cells and Inhibit Botulinum Neurotoxin with Remarkable Binding Ability and Specificity

Angewandte Chemie (April 29, 2015)
[Read more…]

Landmark Indi Molecular® Publication in Nature Chemistry Suggests PCC Binding Technology May Enable Therapeutics for Previously Undruggable Targets Based on Mutations of A Single Amino Acid

CULVER CITY, CA – (April 13, 2015) – Researchers at Caltech and Indi Molecular announced today a landmark publication in Nature Chemistry suggesting that the PCC (protein catalyzed capture) agent binding technology may enable the creation of highly specific therapeutics for targets that have long been considered undruggable. PCC technology was invented at Caltech and is being commercialized by Indi Molecular.
[Read more…]

GenomeWeb – Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics

GenomeWeb | Dec 19, 2014 | Adam Bonislawski
“As we have talked to pharmaceutical companies, it has become very clear that their interest is in super-binding molecules that can target very low abundance therapeutic targets, things that are really hard to reach with a monoclonal,” said Albert Luderer, CEO.
[Read more…]

Indi Molecular® and Sigma-Aldrich® Establish Collaboration to Explore Use of PCC Technology in Biological Tools

Press Release | 17 December 2014
CULVER CITY, CA — Indi Molecular, the maker of a synthetic replacement for monoclonal antibodies, today announced that it has entered into a co-development agreement with Sigma-Aldrich to explore the use of Indi Molecular’s PCC technology with Sigma-Aldrich’s line of biological tools. PCC (protein catalyzed capture) agent technology is a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. Current systems employ antibody-based biological tools that are used to capture proteins and enable highly sensitive detection. The joint research and development project will explore the use of PCCs to specifically interact with proteins.

[Read more…]

Dr. Doug Fisher to Speak at Life Sciences Summit

Dr. Doug Fisher, to Speak at Life Sciences Summit
October 29, 2014 | New York, NY | www.lifesciencessummit.org

BioCentury – Indi Molecular: Building better binders

BioCentury | 31 March 2014 | Emily Cukier-Meisner
“We’ve been able to create a completely synthetic approach to building binding
molecules,” said Albert Luderer, CEO
[PDF]

Indi Molecular Expands Seed Round to $1.8 Million with Additional $300 from Asset Management Ventures

CULVER CITY, CA — (December 10, 2013) — Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised an additional $300,000 from a new investor, Asset Management Ventures. With this investment, the company has expanded its seed round to a total of $1.8 million. The round was led by InterWest Partners and joined by several angel investors. The funds are being used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. The company also announced that it has published three new papers in recent weeks, appearing in Angewandte Chemie, PLOS One and ACS Nano. All three papers were written in collaboration with researchers at the California Institute of Technology (Caltech), with the goal of furthering the development of PCC technology.

[Read more…]

Indi Molecular Launches with $1.5 Million Seed Round Led by InterWest Partners

September 20, 2013 – Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised a $1.5 million seed round led by InterWest Partners and joined by several angel investors. The funds will be used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. PCCs have several advantages over antibodies, including lower cost, faster development and greater specificity. They are being developed as a replacement for antibodies in in vivo imaging, therapeutics, in vitro diagnostics and biological tools. Indi Molecular, previously an operating division of Integrated Diagnostics (Indi), will now operate as an independent company, while maintaining close ties with its parent company.

[Read more…]

Obama honors biotech pioneer Lee Hood

Puget Sound Business Journal | 4 January 2013 |
Patti Payne
 “Dr. Leroy ‘Lee’ Hood, co-founder and president of the Seattle-based Institute for Systems Biology, has been chosen to receive the highest award bestowed upon scientists by the United States government: the National Medal of Science.” Full Article [subscription required]

Integrated Diagnostics® Launches Imaging Division to Create PET Imaging Probes

Press Release | 13 June 2012

SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has launched a new operating division, InDi Imaging™, that is creating a new generation of PET imaging probes using the company’s innovative protein catalyzed capture (PCC) agent technology. PCCs, initially developed for in vitro molecular diagnostics, will be employed as rationally designed, in vivo diagnostic imaging probes that mimic the properties of antibodies and biologics in PET molecular imaging, with the benefit of being chemically stable, synthetic small-molecules.

[Read more…]